The Two Main Types of Lung Cancer

---

Lung cancer is not one disease, and the type you have shapes the entire treatment plan. There are two main categories, and they behave very differently.

Non-small cell lung cancer (NSCLC) is by far the most common, making up the large majority of cases. It tends to grow more slowly and, crucially, is the type most likely to respond to surgery, targeted therapy and immunotherapy. Small cell lung cancer (SCLC) is less common but more aggressive and faster-growing, and is usually treated with chemotherapy and radiation rather than surgery.

Getting this distinction right — and the precise subtype — is the first job of an experienced thoracic oncology team, because almost everything that follows depends on it.

Why Molecular Testing Changes Everything

---

This is the single most important thing to understand about modern lung cancer treatment, and it is the question most worth asking your hospital. Many non-small cell lung cancers carry specific genetic changes — called driver mutations, with names like EGFR, ALK and ROS1 — that drive the cancer's growth.

When a tumour has one of these mutations, there are targeted drugs designed to switch it off. The impact is dramatic: targeted therapy has lifted median survival for some patients from around a year to multi-year survival. But you can only benefit if the mutation is found — which means your tumour must be tested.

So the essential question is: has my tumour been tested for driver mutations? India's leading referral and academic centres routinely perform this molecular profiling, but it is not universal everywhere. Confirming your hospital does it can open up far more effective treatment than chemotherapy alone.

How Lung Cancer Is Treated

---

Treatment depends on the type, the stage and the tumour's molecular profile. Most patients have a combination, chosen by a multidisciplinary team.

Surgery offers the best chance of cure for early-stage NSCLC. Options range from removing a single lobe (lobectomy) or a smaller segment, to removing a whole lung (pneumonectomy) where needed — increasingly done with minimally invasive, keyhole techniques that speed recovery. Radiation therapy treats tumours that cannot be operated on, or mops up after surgery.

Chemotherapy remains important, especially for SCLC and advanced disease. Targeted therapy attacks the specific driver mutation in your tumour, and immunotherapy harnesses your immune system — both have transformed outcomes in advanced lung cancer, often with fewer side effects than chemotherapy.

The right combination is a decision for a tumour board, not a single doctor — one of the key things to confirm when choosing a hospital, as our guide on how to choose a cancer hospital explains.

Success Rates — What to Expect

---

Lung cancer outcomes depend heavily on the stage at diagnosis and the type. Early-stage, operable non-small cell lung cancer can be cured with surgery. For advanced disease, the picture has improved dramatically — targeted therapy and immunotherapy now allow many patients to live well for years, where once the outlook was measured in months.

The progress is real and measurable. Targeted therapy has lifted five-year survival figures for patients with driver mutations far above the historical average, and immunotherapy combined with surgery has shown strong event-free survival in studies of operable NSCLC.

As with every cancer, be cautious of any hospital quoting a single success rate without knowing your type, stage and molecular profile. A responsible thoracic oncologist talks about your specific outlook, because a stage I operable NSCLC and an advanced SCLC are entirely different situations.

Cost of Lung Cancer Treatment in India

---

Lung cancer treatment in India typically costs 60 to 80 percent less than in the United States or United Kingdom, with the same surgery, the same drugs and the same molecular testing. The ranges below are broad guides for the treatment itself at a good private hospital.

Treatment	India	USA (private)
Surgery (lobectomy / pneumonectomy)	USD 4,800–7,800	USD 30,000–60,000
Chemotherapy (per cycle)	USD 400–1,500	USD 3,000–7,000
Radiation therapy (full course)	USD 3,500–6,000	USD 15,000–50,000
Targeted therapy (per month)	USD 1,400–3,000	USD 10,000–20,000
Immunotherapy (per dose)	USD 1,000–4,000	USD 5,000–15,000

Targeted therapy and immunotherapy are ongoing costs that continue for as long as they work, so factor in the monthly figure over time. For the full cross-treatment picture and the total trip cost, see our breakdown of cancer treatment cost in India.

Best Hospitals for Lung Cancer in India

---

For lung cancer, you want a centre with a dedicated thoracic oncology team, in-house molecular testing, and the full range of surgery, radiation, targeted therapy and immunotherapy under one roof. Accreditation and surgical volume matter as much here as in any cancer.

In Delhi NCR, Medanta, Gurgaon is widely cited for thoracic oncology, and Fortis FMRI offers high-volume surgery with molecular diagnostics; both feature in our best cancer hospitals in Delhi NCR guide.

In Mumbai, Kokilaben offers advanced surgery and radiation for lung cancer, compared with the city's others in our best cancer hospitals in Mumbai guide. In South India, Manipal, Bengaluru and Apollo, Chennai both run strong thoracic programmes, set out in our best cancer hospitals in Bangalore and Chennai guide.

For the full national picture of how these hospitals compare on accreditation, volume and technology, start with our pillar guide to the best cancer hospitals in India. For another common cancer treated the same evidence-based way, see our guide to breast cancer treatment in India.